Journal
ACTA PHARMACEUTICA SINICA B
Volume 12, Issue 8, Pages 3233-3254Publisher
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2022.02.023
Keywords
Biomimetic; Cell membrane-coated nanoparticles; Drug delivery; Self markers; Tumor targeting; Cancer immunotherapy; Cancer vaccines; Immune checkpoint blockade inhibitors
Categories
Funding
- National Natural Science Foundation of China (China) [81773648, 81973267]
Ask authors/readers for more resources
Cancer immunotherapy effectively inhibits cancer progression by activating the autoimmune system. Cell membrane-coated nanoparticles have unique functions that allow for precise drug delivery and improved cancer immunotherapy effectiveness.
Cancer immunotherapy can effectively inhibit cancer progression by activating the autoimmune system, with low toxicity and high effectiveness. Some of cancer immunotherapy had positive effects on clinical cancer treatment. However, cancer immunotherapy is still restricted by cancer heterogeneity, immune cell disability, tumor immunosuppressive microenvironment and systemic immune toxicity. Cell membrane-coated nanoparticles (CMCNs) inherit abundant source cell-relevant functions, including self' markers, cross-talking with the immune system, biological targeting, and homing to specific regions. These enable them to possess preferred characteristics, including better biological compatibility, weak immunogenicity, immune escaping, a prolonged circulation, and tumor targeting. Therefore, they are applied to precisely deliver drugs and promote the effect of cancer immunotherapy. In the review, we summarize the latest researches of biomimetic CMCNs for cancer immunotherapy, outline the existing specific cancer immune therapies, explore the unique functions and molecular mechanisms of various cell membrane-coated nanoparticles, and analyze the challenges which CMCNs face in clinical translation. (C) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available